OverviewHOME > About us > Overview
KOSPI KOSPI-listed company (KSE: 011000) (Date of listing : 16 November 1987)
researches and develops DNA vaccines and Plasmid-based Biomedicines
VGXI, Inc. is a wholly-owned subsidiary of GeneOne, which specializes in
the cGMP production of plasmids for use in human clinical trials
07 IND approval for GLS-5700 (Zika DNA vaccine) Phase I clinical study from Health Canada
Health Products and Food Branch
06 IND approval for GLS-5700 (Zika DNA vaccine) Phase I clinical study from US FDA
11IND approval for GLS-5300 (MERS DNA vaccine) Phase I clinical study from US FDA
04IND approval for INO-4212 (Ebola DNA vaccine) Phase I clinical study from US FDA
05Awarded with "The Osong R&D Grand Prize" by MFDS
03VGXI, Inc. awarded as "Best CMO" by World Vaccine Congress, 7th Annual ViE Awards
03Renamed as GeneOne Life Science, Inc.
10IND approval for VGX-6150 (HCV DNA vaccine) Phase I clinical study
09Selected as the Technology Innovative Company (INNOBIZ)
04VGXI, Inc. awarded as "Best CMO" by World Vaccine Congress, 6th Annual ViE Awards
02Establishes corporate R&D center
11IND approval for VGX-3400 (Influenza DNA vaccine) phase I clinical study
05 VGXI, Inc. established as CMO manufacturing facility for cGMP plasmid DNA for use in clinical trials
- Located in The Woodlands, Texas
- Wholly owned subsidiary of VGXI International, Inc.
11 Expansion into pharmaceuticals (specializing in DNA vaccine development)
Renamed as VGX International, Inc.
01 Company established in Korea (Dong Yeom, Inc.)